Last reviewed · How we verify
NCT03304132
The Oral Microbiome and Upper Aerodigestive Squamous Cell Cancer
trial testing Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach in Oral Cancer in 560 participants. Completed in 1 December 2010.
1 December 2010
Quick facts
| Lead sponsor | NYU Langone Health |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 560 |
| Start date | 1 December 1992 |
| Primary completion | 1 December 2010 |
| Estimated completion | 1 December 2010 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach
- Classification of Oral Microbiome Using taxonomic approach
Conditions studied
- Oral Cancer — all drugs for Oral Cancer →
Sponsor
NYU Langone Health — full company profile →
Who can join
Adults 40 to 92, any sex, with Oral Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The human oral cavity is a diverse habitat that contains approximately 700 prokaryotic species. The oral microbiome is comprised of 44% named species, 12% isolates representing unnamed species, and 44% phylotypes known only from 16S rRNA based cloning studies (http://www.homd.org/). Species from 11 phyla have been identified: Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Spirochaetes, Fusobacteria, TM7, Synergistetes, Chlamydiae, Chloroflexi and SR1 (http://www.homd.org/). Because these observations have been mainly based on data generated from traditional Sanger sequencing, the diversity of oral microbiome is highly likely underestimated. Application of high throughput sequencing to the oral microbiome similar to the scale of the microbiome studies of other body sites (GI tract, skin, and vagina) under the Human Microbiome Project is necessary to obtain data essential for understanding the diversity and community structure of the oral microbiome in health and disease.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Opportunities and Challenges of the Human Microbiome in Ovarian Cancer.
Cheng H, Wang Z, Cui L, Wen Y, et al · · 2020 · cited 27× · PMID 32133297 · DOI 10.3389/fonc.2020.00163
Verify or expand the search:
- PubMed search for NCT03304132
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Oral Cancer
Currently open trials in the same condition.
- NCT07509619 — AI-based Physiotherapy Evaluation System for Range of Motion in Oral Cancer Patients · recruiting
- NCT07260344 — Evaluation of Two Non-Invasive Methods, High-Resolution Microendoscopy and Liquid-Based Cytology, for Detection of Oral · NA · recruiting
- NCT06682494 — Enhancing Oral Cancer Awareness · NA · recruiting
- NCT07095608 — Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain · NA · recruiting
- NCT07296250 — Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT · NA · recruiting
Other NYU Langone Health trials
Trials by the same sponsor.
- NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
- NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
- NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
- NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
- NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03304132 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
- Last refreshed: 9 October 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03304132.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing